Thomas Cluzeau

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Thomas Cluzeau

Dec 5, 2024, 18:44 | Insight

Clinical perspectives on post-induction maintenance therapy in patients with AML

A recent paper by Kendra Sweet and Thomas Cluzeau was mentioned by Mohamed Benlazar, Professor of…

Sep 4, 2024, 17:52 | Blog

Ryan Fitzpatrick: The 6th annual MPN MDS EU Focus meeting by MD Education

Ryan Fitzpatrick, CEO and Founder, MD Education, shared a post on LinkedIn: "A great 2 day…

Jul 21, 2024, 20:39 | Blog

Matteo Della Porta: The final analysis of the COMMANDS trial comparing Luspatercept vs Epoetin alfa

Matteo Della Porta, Professor of Hematology at Humanitas University and Head of CALR (Center for…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023